OTCMKTS:BCTXF

BriaCell Therapeutics (BCTXF) Stock Price, News & Analysis

$2.19
-0.13 (-5.60%)
(As of 04/24/2024 ET)
Today's Range
$2.19
$2.31
50-Day Range
$2.02
$3.57
52-Week Range
$3.25
$17.50
Volume
22,628 shs
Average Volume
1,859 shs
Market Capitalization
$1.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BCTXF stock logo

About BriaCell Therapeutics Stock (OTCMKTS:BCTXF)

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BCTXF Stock Price History

BCTXF Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Closing Bell: Briacell Therapeutics Corp flat on Monday (BCT)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
BriaCell Therapeutics (BCT) Gets a Buy Rating from H.C. Wainwright
BriaCell Therapeutics to Spin Off Certain Assets
BriaCell Sees Positive Survival Data in Ongoing Trial
BriaCell to Investigate Potential Stock Manipulation
See More Headlines
Receive BCTXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:BCTXF
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
$-3,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4.55) per share

Miscellaneous

Free Float
N/A
Market Cap
$1.79 million
Optionable
Not Optionable
Beta
1.09
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • William V. Williams
    President, Chief Executive Officer & Director
  • Gadi Levin
    Chief Financial Officer & Secretary
  • Farrah Dean
    Manager-Corporate Development & IR Contact

BCTXF Stock Analysis - Frequently Asked Questions

How have BCTXF shares performed in 2024?

BriaCell Therapeutics' stock was trading at $5.85 at the start of the year. Since then, BCTXF stock has decreased by 62.6% and is now trading at $2.19.
View the best growth stocks for 2024 here
.

How do I buy shares of BriaCell Therapeutics?

Shares of BCTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BCTXF) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners